PATENT CLAIM ANALYSIS

Application Number: 15898730
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "220000"]

Abstract:
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.

Claim (Index 16):
The method of  claim 15 , wherein the diagnostic hepatobiliary function endpoint is alanine aminotransferase (\u201cALT\u201d), serum glutamic-pyruvic transaminase (\u201cSGPT\u201d), aspartate aminotransferase (\u201cAST,\u201d \u201cSGOT\u201d), ALT/AST ratios, serum aldolase, alkaline phosphatase (\u201cALP\u201d), ammonia levels, bilirubin, gamma-glutamyl transpeptidase (\u201cGGTP,\u201d \u201c\u03b3-GTP,\u201d \u201cGGT\u201d), leucine aminopeptidase (\u201cLAP\u201d), liver biopsy, liver ultrasonography, liver nuclear scan, 5\u2032-nucleotidase, or blood protein.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 88.0
- Lexical Diversity: 1.125
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12562621', '15388960', '15627145', '15017480', '15338214']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7785167203975301
- 35 USC 102 Novelty (BERT): 0.5225667811860853
- Combined Prediction Score: 0.7529217264763857
- Mean Citation Score: 255.78134
- Max Citation Score: 298.57587
- Similarity Product: 181.65868088692545

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test